Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe the development and progression of neuropathy and related findings among patients with type 1 diabetes who participated in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. RESEARCH DESIGN AND METHODS: The main diabetic peripheral neuropathy (DPN) outcome was assessed using clinical symptoms, signs, and nerve conduction study results during DCCT and repeated in EDIC year 13/14. Cardiovascular autonomic neuropathy (CAN) was assessed by R-R response to paced breathing, Valsalva ratio, and blood pressure response to standing during DCCT and in EDIC years 13/14 and 16/17. Additionally, symptoms reflecting neuropathic pain and autonomic function (including hypoglycemia awareness) were collected yearly in EDIC using standardized questionnaires; peripheral neuropathy was also assessed annually using the Michigan Neuropathy Screening Instrument. Assessments of genitourinary function were collected at EDIC year 10. RESULTS: Intensive therapy during the DCCT significantly reduced the risk of DPN and CAN at DCCT closeout (64% and 45%, respectively, P < 0.01). The prevalence and incidence of DPN and CAN remained significantly lower in the DCCT intensive therapy group compared with the DCCT conventional therapy group through EDIC year 13/14. CONCLUSIONS: The persistent effects of prior intensive therapy on neuropathy measures through 14 years of EDIC largely mirror those observed for other diabetes complications. DCCT/EDIC provides important information on the influence of glycemic control, and the clinical course of diabetic neuropathy, and, most important, on how to prevent neuropathy in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Diabetes Control and Complications Trial (DCCT) and its observational follow-up study, Epidemiology of Diabetes Interventions and Complications (EDIC), conclusively demonstrated that intensive glucose control applied early in the course of type 1 diabetes (T1D), significantly reduces the risk of developing CAN [2–4].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 1×
“Painful symptoms are frequently refractory to treatment, and loss of protective sensation heightens the risk for foot ulceration and lowerextremity amputations (19,20).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1239 · Cited by 957
Self-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1895 · Cited by 578 · cited 1×
“Yet, CAN is an independent predictor of mortality (21,22), possibly by promoting life-threatening arrhythmias and sudden death in response to a variety of insults including drug side effects, hypoglycemia, hypokalemia, hypotension, or ischemia (23).”
Background
Cited by
Items 201–300 of 572
Hansen, C. S., Lundby-Christiansen, L., Tarnow, L., Gluud, C. N., Hedetoft, C., Thorsteinsson, B., Hemmingsen, B., Wiinberg, N., Sneppen, S. B., Lund, S. S., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01131-3 · Cited by 21
“Prevalence rates of DPN have been reported to vary from 10 to 41% [4, 5].”
BackgroundRyk, A., Łosiewicz, A., Michalak, A., & Fendler, W. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249723 · Cited by 21
“Although DCCT and EDICT trials reported that some patients receiving intensified treatment also developed neuropathies [13], the perspective on optimal glycemic control has considerably evolved since then.”
Zhang, B., Yu, Y., Aori, G., Wang, Q., Kong, D.-W., Yang, W., Guo, Z., & Zhang, L. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/2789847 · Cited by 21
“DPNP is characterized by spontaneous pain, hyperalgesia, and allodynia, some of which even progressed to hypoalgesia at advanced stage, which often leads to sleep disorder and depression and passively affects patients’ health-related quality of life [3].”
BackgroundDiabetes Distal Peripheral Neuropathy: Subtypes and Diagnostic and Screening Technologies
Lew, K. N., Arnold, T. C., Cantelmo, C. B., Jacque, F., Posada-Quintero, H. F., Luthra, P., & Chon, K. H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035375 · Cited by 20
Christensen, M. M. B., Hommel, E. E., Jørgensen, M. E., von Scholten, B. J., Fleischer, J., & Hansen, C. S. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0249 · Cited by 20
Non-coding RNA regulators of diabetic polyneuropathy
Meydan, C., Üçeyler, N., & Soreq, H. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135058 · Cited by 20
Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy
Lee, K. A., Park, T. S., & Jin, H. Y. (2020) · Endocrine · doi:10.1007/s12020-020-02473-4 · Cited by 20
Purohit, S. B., Tran, P. M. H., Tran, L. K. H., Satter, K. B., He, M., Zhi, W., Bai, S., Hopkins, D., Gardiner, M., Wakade, C. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654233 · Cited by 20
“The Diabetic Control and Complications Trial/Epidemiology of Diabetes and Complications (DCCT/EDIC) study suggests that despite intensive glycemic control, incidence and prevalence of DPN increased in both the subjects under intensive (7% incidence) and permissive (17% incidence) glycemic control (9, 10).”
BackgroundGreco, C., Nascimbeni, F., Carubbi, F., Andreoné, P., Simoni, M., & Santi, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194466 · Cited by 20
Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy (DSPN)
Sharma, S., & Rayman, G. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1165505 · Cited by 20
“The impact of intensive glycaemic control in retarding the progression of DSPN has been well demonstrated in type 1 diabetes in the DCCT/EPIC study (69) but specific evidence to suggest the same is lacking in type 2 diabetes (70, 71).”
BackgroundThe influence of food order on postprandial glucose levels in children with type 1 diabetes
Faber, E. M., van Kampen, P. M., Boers, A. C.-D., Houdijk, E. C. A. M., & van der Kaay, D. C. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12640 · Cited by 20
Diabetic Neuropathy: A Guide to Pain Management
Zhang, E. X., Yazdi, C., Islam, R. K., Anwar, A. I., Alvarez-Amado, A. V., Townsend, H., Allen, K. E., Plakotaris, E., Hirsch, J. D., Rieger, R., et al. (2024) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01293-9 · Cited by 19
“In an epidemiological study, the prevalence of DPN among adults with type 1 DM (T1DM) increased from 6% at baseline to 30% after 13 years [6].”
Nabrdalik, K., Irlik, K., Meng, Y., Kwiendacz, H., Piaśnik, J., Hendel, M., Ignacy, P., Kulpa, J., Kegler, K., Herba, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02367-z · Cited by 19
“The prevalence of CAN increases with DM duration in both type 1 DM (T1DM) and type 2 DM (T2DM) with up to 30% [2, 3] and 60% after 20 years being diagnosed and after 15 years of DM duration [4] respectively.”
BackgroundMing, S., Lei, Z., & Jie, W. (2025) · Interdisciplinary Research in Medical Sciences Specialty · doi:10.51847/2at3p1kejs · Cited by 19
Lysy, Z., Lovblom, L. E., Halpern, E. M., Ngo, M., Ng, E., Orszag, A., Breiner, A., Bril, V., & Perkins, B. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106995 · Cited by 19
“The prevalence of clinical DSP observed in this cohort was comparable to previous reports.[37] All subgroups had similar gender distributions, smoking prevalence, and lipid profiles.”
ResultRegression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus
Son, M. K., Yoo, H. Y., Kwak, B. O., Park, H. W., Kim, K. S., Chung, S., Chae, H. W., Kim, H.-S., & Kim, D. H. (2015) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2015.20.1.13 · Cited by 19
Neuropatía diabética y pie diabético
Vázquez, F., Mauricio, D., & Julià, J. V. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.004 · Cited by 19
Astasio-Picado, Á., Martínez, E. E., & Martín, B. G. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190206160711 · Cited by 19
The Epidemiology of Diabetic Neuropathy
Hansen, C. S., Määttä, L. L., Andersen, S. T., & Charles, M. H. (2023) · Contemporary Diabetes · doi:10.1007/978-3-031-15613-7_2 · Cited by 17
Omaña, H., Madou, E., Montero‐Odasso, M., Payne, M. W. C., Viana, R., & Hunter, S. W. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999201001203652 · Cited by 17
Feng, Z., Guo, Q., Wang, W., Yuan, Y., Jin, X., Zhou, H., Liu, J., Lei, H., Yang, X., Liu, J., et al. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00739-z · Cited by 17
Steigmann, L., Miller, R., Trapani, V. R., Giannobile, W. V., Braffett, B. H., Pop‐Busui, R., Lorenzi, G. M., Herman, W. H., & Sarma, A. V. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108120 · Cited by 17
Self-citationHueros, J. I. C., Hidalgo-Barquero, M. V. M., Morales-Gabardino, J. A., & Buitrago, F. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.11.015 · Cited by 16
Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes
Pola, S., Shah, S. R., Pingali, H., Zaware, P., Thube, B. R., Makadia, P., Patel, H., Bandyopadhyay, D., Rath, A., Giri, S. R., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116071 · Cited by 16
Pop‐Busui, R., Braffett, B. H., Wessells, H., Herman, W. H., Martin, C. L., Jacobson, A. M., & Sarma, A. V. (2021) · Diabetes Care · doi:10.2337/dc21-1276 · Cited by 16
Self-citationDiabetes Complications in Childhood Diabetes: New Biomarkers and Technologies
Bjornstad, P., & Maahs, D. M. (2015) · Current Pediatrics Reports · doi:10.1007/s40124-015-0081-0 · Cited by 16
Neuropathy in the DCCT/EDIC—What Was Done Then and What We Would Do Better Now
Pop‐Busui, R., & Martin, C. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.020 · Cited by 16
Self-citationDiabetic Peripheral and Autonomic Neuropathy
Ziegler, D. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch40 · Cited by 16
Şalvız, E. A., Onbasi, S., Özonur, A., Sungur, M. O., Berköz, Ö., & Tugrul, K. M. (2017) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2017.01.009 · Cited by 16
“However, in another study, strict glycemic control was shown to be effective in type 1 diabetes.(23) Charles et al(24) found that early detection and intensive treatment of type 2 DM had no effect on the prevalence of diabetic peripheral neuropathy.”
BackgroundKurz, F. T., Jende, J. M. E., Salomir, R., Lövblad, K., Lascano, A. M., & Gariani, K. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/9080699 · Cited by 15
Haque, F., Reaz, M. B. I., Chowdhury, M. E. H., Ali, S. H. M., Bakar, A. A. A., Rahman, T., Kobashi, S., Dhawale, C. A., & Bhuiyan, M. A. S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104954 · Cited by 15
Yu, C., Zhuang, L., Xu, F., Zhao, L.-H., Wang, X., Wang, C., Ning, L.-Y., Zhang, X., Zhang, D., Wang, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.997672 · Cited by 15
“An abnormality of nerve conduction studies was defined by the presence of at least one abnormal nerve attribute (of latency, amplitude or nerve conduction velocity) in two or more nerves of the lower limbs and upper limbs (27).”
BackgroundMooshage, C. M., Schimpfle, L., Κender, Ζ., Szendroedi, J., Heiland, S., Nawroth, P. P., Bendszus, M., Kopf, S., Kurz, F. T., & Jende, J. M. E. (2022) · Diabetes · doi:10.2337/db22-0548 · Cited by 15
A Review on Autonomic Functional Assessment in Diabetic Patients
Rukadikar, C. A., Rukadikar, A. R., & Kishore, S. (2023) · Cureus · doi:10.7759/cureus.34598 · Cited by 15
“In summary, studies have shown that duration of diabetes, age, vascular complications, glycemic control (polyneuropathy, nephropathy, retinopathy, etc.), and comorbidities (e.g., dyslipidemia/hypercholesterolemia, hypertension) were all risk factors for DAN [18].”
BackgroundInfluentialMcEwan, P. C., Bennett, H., Fellows, J., Priaulx, J., & Bergenheim, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162441 · Cited by 15
Limonte, C. P., Valo, E., Montemayor, D., Afshinnia, F., Ahluwalia, T. S., Costacou, T., Darshi, M., Forsblom, C. M., Hoofnagle, A. N., Groop, P., et al. (2020) · American Journal of Nephrology · doi:10.1159/000510830 · Cited by 15
Kuwelker, S., Prichard, D. O., Bailey, K. R., & Bharucha, A. E. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14154 · Cited by 15
Diagnosis of diabetic polyneuropathy in primary care
Khramilin, V. N., Strokov, I. A., Давыдов, О. С., & Churyukanov, M. V. (2021) · Russian Journal of Pain · doi:10.17116/pain20211902147 · Cited by 15
Shi, C., Wang, C., Bai, R., Zhang, X., Men, L., & Du, J. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2730 · Cited by 15
Inzucchi, S. E., & Majumdar, S. K. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.018 · Cited by 15
Ng, S. M., Malene, I., Nilar, M., Rassavong, K., Vu, C. D., Tan, F. H. S., Jalaludin, M. Y., Toomey, C., & Lek, N. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109868 · Cited by 14
Autonomic neuropathy in diabetes
Tannus, L. R. M., & Cobas, R. A. (2026) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2025-0406 · Cited by 15
“…signaling affects T1D and T2D differently: in T2D, insulin resistance limits metabolic and bioenergetic function, and compromise axonal growth and myelination in peripheral nerves (19,32), whereas in T1D, preserved insulin sensitivity allows better neuropathic outcomes with insulin therapy (33).”
InfluentialRasmussen, V. F., Thrysøe, M., Nyengaard, J. R., Tankişi, H., Karlsson, P., Hansen, J., Krogh, K., Brock, C., Kamperis, K., Madsen, M., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110736 · Cited by 14
Nguyen, H. T., Tuan, A. N., Thi, T. A. D., Van, K. T., Le-Nhat-Thuy, G., Thị, P. H., Thi, Q. G. N., Cham, B. T., Quang, H. T., & Nguyen, T. V. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129566 · Cited by 14
Jadhao, P. A., Swain, J., Das, S., Mangaraj, S., & Sravya, S. L. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998282818240125110248 · Cited by 14
An Overview on Diabetic Neuropathy
Singh, U., Sharma, R., & Kumar, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998295741240606104106 · Cited by 14
Diabetic autonomic neuropathy.
Vučković-Rebrina, S., Barada, A., & Duvnjak, L. S. (2013) · Diabetologia Croatica · Cited by 14
Renal function is highly associated with podiatric risk in diabetic patients
Bonnet, J., Szwarc, I., Avignon, A., Jugant, S., & Sultan, A. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad106 · Cited by 13
“HbA1c had no impact on the risk stage, whereas intensive insulin therapy showed some impact on PND, retinopathy and nephropathy in diabetes type 1 [27].”
BackgroundZarrin, R., Ayremlou, P., & Ghassemi, F. (2016) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.41718 · Cited by 13
Ren, L., Guo, R., Fu, G., Zhang, J., & Wang, Q. (2022) · Medicine · doi:10.1097/md.0000000000029032 · Cited by 13
Li, X., Hao, W., Lin, S., & Yang, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1361707 · Cited by 13
“Diabetic Peripheral Neuropathy (DPN) Diagnosis: A comprehensive assessment integrated clinical, neurological examinations, and nerve conduction studies, adhering to recognized guidelines (34).”
BackgroundNurcahyanti, A. D. R., Arieselia, Z., Kurniawan, S. V., Sofyan, F., & Wink, M. (2018) · Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review · doi:10.4103/phrev.phrev_20_17 · Cited by 13
Effects of Root Extract of Ruellia tuberosa L. on Kidneys of Diabetic Rats
Safitri, A., Srihardyastutie, A., Roosdiana, A., Aulanni’am, A., & Octaviana, E. N. L. (2019) · Journal of Mathematical and Fundamental Sciences · doi:10.5614/j.math.fund.sci.2019.51.2.3 · Cited by 14
“Formation of such reactive oxygen species increases lipid modification, DNA, and proteins in various tissues [12,13].”
BackgroundCurrent Approaches in the Administration of Chronic Complications Related to Diabetes
Yuksel, M., & Bektaş, H. (2020) · Turkiye Klinikleri Journal of Nursing Sciences · doi:10.5336/nurses.2019-70201 · Cited by 13
Alsarhan, A. A., Amawi, K. F., Almazari, I., Hurirah, H. A., & Alkhatib, A. J. (2020) · Analytical Cellular Pathology · doi:10.1155/2020/3906583 · Cited by 13
“Type 1 diabetic patients who are under well management can suffer from damage in peripheral organs related to diabetic complications [13, 14].”
BackgroundImpact of vitamin D level in diabetic people with peripheral neuropathy
Assy, M. H., Draz, N. A., Fathy, S. E., & Hamed, M. G. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00370-9 · Cited by 13
“Also, Martin and colleagues [16] tried to assess the effectiveness of vitamin D supplementation on patients with DPN and found that vitamin D supplementation together with exercise reduced both symptoms and complications of DPN.”
BackgroundCarbohydrate counting as a strategy to optimize glycemic control in type 1 diabetes mellitus
Centenaro, A., do Nascimento, C., Beretta, M. V., & Rodrigues, T. D. C. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000596 · Cited by 12
“The total number of nutritional consultations carried out between 2014 and 2018 was also higher in the CC group [10 (6-14) vs.”
BackgroundTemporal Trends in Distal Symmetric Polyneuropathy in Type 2 Diabetes: The Fremantle Diabetes Study
Davis, W. A., Hamilton, E. J., & Davis, T. M. E. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad646 · Cited by 12
Roohi, T. F., Mehdi, S., Aarfi, S., Krishna, K. L., Pathak, S., Suhail, S. M., & Faizan, S. (2023) · Diabetology International · doi:10.1007/s13340-023-00680-8 · Cited by 12
“Approximately, one-third of all patients with uncontrolled diabetes may develop DN and may require renal dialysis [20, 21].”
Evaluation of cardiac autonomic dysfunctions in children with type 1 diabetes mellitus
Gözüküçük, D., İleri, B. A., Karaca, S., Öztarhan, E., Güller, D., Önal, H., & Öztarhan, K. (2024) · BMC Pediatrics · doi:10.1186/s12887-024-04644-y · Cited by 12
“Studies have established a correlation between autonomic function disorders and factors such as age, prolonged diabetes duration, and poorly maintained metabolic control, with increased prevalence in patients exhibiting poor glycemic control [5].”
BackgroundRuban, A., Glaysher, M. A., Miras, A. D., Goldstone, A. P., Prechtl, C. G., Johnson, N. A., Li, J. V., Aldhwayan, M., Aldubaikhi, G., Glover, B., et al. (2020) · Efficacy and Mechanism Evaluation · doi:10.3310/eme07060 · Cited by 12
Peripheral and Autonomic Neuropathy in Diabetes
Pop‐Busui, R., Boulton, A. J. M., & Sosenko, J. M. (2018) · Cited by 12
Self-citationXia, X., Dai, L., Zhou, H., Chen, P., Liu, S., Yang, W., Zuo, Z., & Xu, X. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.110007 · Cited by 12
da Matta, M. D. F. B., Traon, A. P., Perez‐Lloret, S., Laporte, C., Berdugo, I., Nasr, N., Hanaire, H. P., & Sénard, J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/5601351 · Cited by 12
Mmonu, N. A., Malaeb, B. S., Hotaling, J. M., Braffett, B. H., Holt, S. K., Dunn, R. L., Palmer, M. R., Martin, C. L., Jacobson, A. M., Herman, W. H., et al. (2020) · International Journal of Impotence Research · doi:10.1038/s41443-020-0242-8 · Cited by 12
Self-citationDiabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neumann, S. A. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_10 · Cited by 13
Ezzatvar, Y., Hormazábal‐Aguayo, I., Muñoz‐Pardeza, J., Páez‐Herrera, J., Sepulveda, R. A. Y., & García‐Hermoso, A. (2025) · Pediatric Diabetes · doi:10.1155/pedi/8398194 · Cited by 11
“Maintaining good metabolic stability during this period can prevent or delay endothelial damage and the onset and progression of microvascular complications [83].”
Dhillon, S., Fithrie, A., & Batubara, C. A. (2023) · Journal of Society Medicine · doi:10.47353/jsocmed.v2i4.47 · Cited by 11
Ring, M., & Davalos, L. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2023.12.002 · Cited by 11
An analysis of urodynamic parameters in diabetic and nondiabetic women
Burns, R. T., Arnold, P. J., Song, L., MOSS, K. L., & Powell, C. R. (2024) · Neurourology and Urodynamics · doi:10.1002/nau.25510 · Cited by 11
“28,29 The data regarding the effect of tight glycemic control on DBD is not quite as clear.”
Bennett, H., Tank, A., Evans, M., Bergenheim, K., & McEwan, P. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13992 · Cited by 11
Alkhudhayri, S., Sajini, R., Alharbi, B., Qabbani, J., Alhindi, Y. Z., Fairaq, A., & Yousef, A. M. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.209 · Cited by 11
Orthostatic blood pressure changes and diabetes duration
Idiaquez, J. F., Lovblom, L. E., Perkins, B. A., & Bril, V. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108169 · Cited by 11
Buckley, C. M., Ali, F., Roberts, G. A., Kearney, P. M., Perry, I. J., & Bradley, C. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000069 · Cited by 11
“36 In our study, even 7 years of diabetes management in secondary healthcare services did not prevent LEA. Intensive therapy should be initiated as early as possible in the attempt to reduce HbA1c levels to target and prevent LEA.”
BackgroundComparing Real-Time Self-Tracking and Device-Recorded Exercise Data in Subjects with Type 1 Diabetes
Groat, D., Kwon, H., Grando, A., Cook, C. B., & Thompson, B. (2018) · Applied Clinical Informatics · doi:10.1055/s-0038-1676458 · Cited by 11
Zhao, W., Lu, J., Zhang, L., Lu, W., Zhu, W., Bao, Y., & Zhou, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002140 · Cited by 11
“As up to half of the patients may be asymptomatic, early diagnosis is difficult in many cases, leading to delayed treatment and therefore higher risk of foot ulceration and increased mortality.([2,17]) Quantitative evaluation of small fiber injury is the key to early diagnosis of DSPN.”
BackgroundPainful diabetic polyneuropathy: evidence-based diagnosis and treatment
Khramilin, V. N., & Давыдов, О. С. (2021) · Russian Journal of Pain · doi:10.17116/pain20211904144 · Cited by 10
Salama, R. A. M., Raafat, F. A., Hasanin, A. H., Hendawy, N., Saleh, L. A., Habib, E. K., Hamza, M., & Hassan, A. N. E.-D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111533 · Cited by 10
The time to develop treatments for diabetic neuropathy
Rendell, M. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868433 · Cited by 10
Ntavidi, S., Katsanou, P., Marakomichelakis, G., Kasdagli, M., Antiochou, E., Mpali, I., Kakou, A.-M., Tsioufis, K. P., Dimitriadis, G., & Lambadiari, V. (2022) · Nutrients · doi:10.3390/nu15010072 · Cited by 10
El-Badawy, M. A., Farrag, D. A., AbdelRehem, S. M. R., Elmahdi, A. R., El-Sherbeny, A. A., Hady, E. A. M. A., Abdelsattar, H. A., & Abdelaziz, D. M. (2017) · Egyptian Rheumatology and Rehabilitation · doi:10.4103/1110-161x.205663 · Cited by 10
The impact of pancreas transplantation on diabetic complications: A systematic review
Giri, G., Doherty, D. T., Azmi, S., Khambalia, H. A., Giuffrida, G., Moinuddin, Z. M., & van Dellen, D. (2025) · Transplantation Reviews · doi:10.1016/j.trre.2025.100910 · Cited by 9
Vágvölgyi, A., Maróti, Á., Szűcs, M., Póczik, C., Urbán-Pap, D., Baczkó, I., Nemes, A., Csajbók, É., Sepp, K., Kempler, P., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.719953 · Cited by 9
Pető, A., Tóth, L. I., Hernyák, M., Lőrincz, H., Molnár, Á., Nagy, A. C., Lukács, M., Kempler, P., Paragh, G., Harangi, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306482 · Cited by 9
Temporal trend of autonomic nerve function and HSP27, MIF and PAI-1 in type 1 diabetes
Zimmerman, M., Enes, S. R., Skärstrand, H., Pourhamidi, K., Gottsäter, A., Wollmer, P., Rolandsson, O., Westergren‐Thorsson, G., & Dahlin, L. B. (2017) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2017.03.001 · Cited by 9
“However, recent results from two major trials, the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) studies, show that glucose control is not enough to protect patients with diabetes from development of peripheral neuropathy and CAN [19].”
ResultInfluentialAutomated analysis of corneal nerve tortuosity in diabetes: implications for neuropathy detection
Klisser, J., Tummanapalli, S. S., Kim, J., Chiang, J. C. B., Khou, V., Issar, T., Naduvilath, T. J., Poynten, A. M., Markoulli, M. P., & Krishnan, A. V. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1940875 · Cited by 9
“was no significant difference in tortuosity between T1DM and T2DM groups, despite the differences in neuropathy pathophysiology that are thought to exist between the two forms of diabetes.(28,29)”
BackgroundPrevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review
Carvajal-Moreno, L., Coheña‐Jiménez, M., García-Ventura, I., Pabón‐Carrasco, M., & Belloso, A. J. P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061723 · Cited by 8
“• Study 10: Martin et al., 2014 [15] Methods: Surviving cohort study from the RCT Diabetes Control and Complications Trial and its follow-up study Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) [87,88].”
MethodGreco, C., Cacciani, M., Corleto, R., Simoni, M., Spaggiari, G., & Santi, D. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.07.009 · Cited by 8
Genetic Variants Influence the Development of Diabetic Neuropathy
Hajdú, N., Rácz, R., Tordai, D. Z., Békeffy, M. Z., Vági, O. E., Istenes, I., Körei, A. E., Kempler, P., & Putz, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126429 · Cited by 8
“This underscores the significance of genetic susceptibility in the development of the complications [9,10].”
BackgroundRicciardi, D., Galiero, R., Todisco, V., Tedeschi, G., Loffredo, G., Caturano, A., Rinaldi, L., Cirillo, G., & Sasso, F. C. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.20 · Cited by 8
Fan, X., Yan, G., Cao, J., Zhao, Y., Wang, Y., Wang, X., & Mi, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308537 · Cited by 8
“Nevertheless, the management of blood glucose levels has limited impact on individuals diagnosed with type 2 DPN [8].”
BackgroundМураталина, А., Smith‐Palmer, J., Nurbekova, A., Abduakhassova, G., Zhubandykova, L., Roze, S., Karamalis, M., Shamshatova, G., Demessinov, A., D’Agostino, N. D., et al. (2015) · Value in Health Regional Issues · doi:10.1016/j.vhri.2015.09.002 · Cited by 8
Clinical significance of apelin in the treatment of type 2 diabetic peripheral neuropathy
Xu, H., Wang, Q., Wang, Q., Che, X. Q., Liu, X., Zhao, S., & Wang, S. (2021) · Medicine · doi:10.1097/md.0000000000025710 · Cited by 8
Reduced microvascular reactivity in patients with diabetic neuropathy
Krasulina, K. A., Glazkova, P. A., Glazkov, A. A., Куликов, Д. А., Рогаткин, Д. А., Kovaleva, Y. A., Bardeeva, J. N., & Dreval', A. V. (2021) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-211177 · Cited by 8
Diabetic neuropathy: a focus on the testing method
Danjo, J. (2018) · International Journal of Family & Community Medicine · doi:10.15406/ijfcm.2018.02.00027 · Cited by 8
Diabetic distal symmetric polyneuropathy: More than just “tingling in the feet”
Bell, D. S. H., & Jerkins, T. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70235 · Cited by 7
“27 (Table 1) Tapentadol and Tramadol are also not recommended for similar reasons.”
Wang, Q., & Wang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814383 · Cited by 7
Grace, T., Edgington, A., Reinhart, L., Burkart, T., Dyer, E., Halsey, J., Baroudi, K., Hicks, C., Layne, J. E., & Walker, T. C. (2024) · Clinical Diabetes · doi:10.2337/cd24-0030 · Cited by 7
Corneal confocal microscopy identifies early and definite diabetic cardiac autonomic neuropathy
Azmi, S., Ferdousi, M., Kalteniece, A., Petropoulos, I. N., Alam, U., Ponirakis, G., Asghar, O., Marshall, A. G., Boulton, A. J. M., Efron, N., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112172 · Cited by 7
Jia, Y., Long, D., Song, W., Wang, Q., & Zhang, Q. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09981-6 · Cited by 7
Metadata
- Authors
- Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI
- Corresponding author
- Martin, Catherine L.
- ORCID
- Martin, Catherine L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 31-38
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3868000
- OpenAlex
- W2115038969
- Cited by
- 499
- References
- 30
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 45 · 2023: 38 · 2022: 40 · 2021: 57 · 2020: 50 · 2019: 41 · 2018: 45 · 2017: 28 · 2016: 34 · 2015: 42 · 2014: 23 · 2013: 4
- FWCI
- 27.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- BD
- Roche Diabetes Care
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- Abbott Diabetes Care
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK094176, U01-DK094157, P30DK020572)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- diabetic peripheral neuropathy, cardiac autonomic neuropathy, type 1 diabetes, tight glycemic control, neuropathy progression, neuropathic pain, hypoglycemia awareness, genitourinary function, Michigan Neuropathy Screening Instrument, DCCT/EDIC, neuropathy prevention
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 1, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Neural Conduction, Peripheral Nervous System Diseases, Risk Factors, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.